As of March 2015, complaints against Glucocil include a warning letter from the U.S. Food and Drug Administration directing Neuliven Health to stop selling Glucocil illegally as a diabetes treatment, according to the official FDA website. Such illegally sold products can put people with diabetes at risk of delaying valid treatment.
The 2013 FDA letter informed Neuliven Health that the Glucocil label did not contain sufficient directions for product use and Glucocil was not recognized as effective and safe for the uses advertised. The agency gave the company an opportunity to comply with the alleged violations of the federal law or face penalties such as injunction or seizure, states the FDA.
Consumers should be wary of choosing natural or herbal remedies rather than prescription medications approved by the FDA. They should consider Glucocil and other diabetes-targeting remedies as unsafe for use, explains the FDA. The agency acted to prevent the public from the possibility of harm if consumers substituted Glucocil for appropriate medical care.
Patients and health care professionals are encouraged to notify the FDA of any adverse effects from using any product that claims to manage or treat diabetes and its complications. The agency's MedWatch Adverse Event Reporting program is prepared to accept health fraud notifications by phone, fax, mail or online through its website, notes the FDA.